Literature DB >> 16037924

Suboptimal medication adherence in Parkinson's disease.

Katherine A Grosset1, Ian Bone, Donald G Grosset.   

Abstract

Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single-center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37-74) versus 98% (interquartile range, 93-102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2-20) and those with satisfactory adherence (median, 25%; interquartile range, 11-73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037924     DOI: 10.1002/mds.20602

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  55 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

2.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 3.  Medication nonadherence in Parkinson's disease.

Authors:  Jori E Fleisher; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

4.  Instrumental activities of daily living performance among people with Parkinson's disease without dementia.

Authors:  Erin R Foster
Journal:  Am J Occup Ther       Date:  2014 May-Jun

5.  A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Authors:  Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins
Journal:  Am J Hematol       Date:  2017-09-28       Impact factor: 10.047

6.  New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.

Authors:  Michael A Kelberman; Elena M Vazey
Journal:  Curr Pharmacol Rep       Date:  2016-09-28

7.  The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

Authors:  Thomas E Delea; Simu K Thomas; May Hagiwara
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

Review 8.  Initiation of Parkinson's disease treatment.

Authors:  Heinz Reichmann
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

9.  Impact of medication therapy management in patients with Parkinson's disease.

Authors:  Martina Henrichsmann; Georg Hempel
Journal:  Int J Clin Pharm       Date:  2015-11-21

10.  Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Authors:  Kapil D Sethi; Robert A Hauser; Stuart H Isaacson; Terry McClain
Journal:  Cases J       Date:  2009-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.